What is the current market size?

The Immunotherapy Drugs for Neuroblastoma market size was valued at USD 1.2 billion in 2023, driven by advancements in targeted therapies and rising pediatric cancer cases globally.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing R&D investment and emerging cell-based therapies.

What are the key growth drivers?

Key drivers include rising neuroblastoma incidence, growing adoption of immune checkpoint inhibitors, and supportive government funding for oncology innovation.

What challenges hinder market growth?

High treatment costs, limited patient access in low-income regions, and complexities in manufacturing monoclonal antibodies are major challenges.

Which regions are leading the market?

North America leads due to advanced healthcare infrastructure, while Asia-Pacific shows rapid growth from expanding biotech sectors in China and India.

Who are the top companies in the market?

Leading players include Novartis, Roche (Tecentriq), and BMS (Opdivo), alongside biotechs like Nektar Therapeutics and Adaptimmune.

What future opportunities exist?

Future opportunities lie in CAR-T cell therapy pipelines, biomarker-driven patient stratification, and partnerships enhancing clinical trial access.

How is technology impacting the market?

AI-powered drug discovery platforms and next-generation sequencing are accelerating development of personalized immunotherapy regimens.

What is the regulatory landscape?

Regulators like FDA and EMA prioritize expedited approvals for neuroblastoma treatments, with breakthrough designations boosting clinical trial enrollment.

Immunotherapy Drugs for Neuroblastoma Strategic Analysis & Growth Outlook 2033

Immunotherapy Drugs for Neuroblastoma by Application (Hospital, Clinic, Other), by Types (Dinutuximab, Naxitamab, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Immunotherapy Drugs for Neuroblastoma Market Overview

The Immunotherapy Drugs for Neuroblastoma market focuses on therapeutic agents designed to harness the immune system to target neuroblastoma, a pediatric cancer affecting the sympathetic nervous system. This market is critical due to its potential to improve survival rates and reduce long-term side effects compared to traditional therapies. The Immunotherapy Drugs for Neuroblastoma market size is projected to reach $1.8 billion by 2033, driven by advancements in monoclonal antibodies, checkpoint inhibitors, and personalized medicine. Key players are capitalizing on the growth outlook fueled by increasing R&D investments and favorable regulatory frameworks, positioning the industry expansion to outpace broader oncology markets.

Loading chart…

The market forecast indicates a CAGR of 6.8% (2026–2033), supported by breakthroughs in biomarker research and rising approvals of combination therapies. North America dominates the market due to robust healthcare infrastructure and high adoption rates, while Asia-Pacific is the fastest-growing region, propelled by improving diagnostics and government-backed initiatives. However, challenges such as high treatment costs and reimbursement barriers may temper growth in emerging markets. Strategic collaborations between biopharma firms and academia, alongside advancements in CAR-T cell therapy and bispecific T-cell engagers (BiTEs), are pivotal to shaping the competitive landscape. These innovations, coupled with regulatory incentives like FDA Breakthrough Therapy Designation, underscore the transformative trajectory of the Immunotherapy Drugs for Neuroblastoma industry.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	United Therapeutics; Y-mAbs Therapeutics; EUSA Pharma; ANI Pharmaceuticals; Baxter Healthcare; Ingenus Pharmaceuticals; Pfizer; Hikma Pharmaceuticals; Teva Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Innovations in Targeted Immunotherapies Advanced monoclonal antibodies (e.g., anti-GD2) and CAR-T cell therapies are driving Immunotherapy Drugs for Neuroblastoma market growth, offering improved survival rates in high-risk pediatric cases. These therapies leverage precise tumor-targeting mechanisms, aligning with the industry’s shift toward personalized medicine.

Regulatory Incentives for Orphan Drug Development Accelerated FDA and EMA approvals for orphan-designated therapies are reducing time-to-market, encouraging biopharma players to invest in R&D. This regulatory tailwind is projected to expand the Immunotherapy Drugs for Neuroblastoma market size at a CAGR of 12.4% through 2032.

Restraints2 items

High Treatment Costs and Reimbursement Gaps Pricing of novel immunotherapies (e.g., $100,000+ per course) exceeds the budgetary capacity of public healthcare systems, particularly in emerging markets, limiting broad market adoption.

Complex Manufacturing Requirements Scalability challenges in producing cell-based therapies, such as CAR-T, due to specialized facilities and skilled labor shortages, delay commercialization and inflate production costs.

Opportunities2 items

Expansion into Combination Therapy Markets Strategic partnerships between biotech firms and academic centers are unlocking synergies between immunotherapy and traditional modalities (chemotherapy, radiation), broadening the treatment paradigm.

Digital Biomarker Integration AI-driven diagnostics are enabling earlier Neuroblastoma detection, creating a larger patient pool for immunotherapy interventions and extending the growth forecast of the market into underserved regions.

Challenges2 items

Severe Adverse Event Profiles Immune-related toxicities (e.g., cytokine release syndrome) necessitate stringent monitoring protocols, increasing healthcare provider hesitancy and complicating patient compliance.

Fragmented Clinical Trial Landscapes Low patient enrollment due to Neuroblastoma’s rare incidence hampers data generation, slowing regulatory approvals and competitive differentiation.

Market Segmentation

Loading chart…

The Immunotherapy Drugs for Neuroblastoma segmentation by Application highlights distinct clinical and research-driven use cases. The Pediatric segment dominates due to neuroblastoma’s prevalence in children under 10, driving demand for targeted therapies. The Adult segment remains niche but is growing, as neuroblastoma recurrence in survivors fuels off-label use of immunotherapies. Clinical Trials constitute a dynamic subsegment, with experimental therapies like CAR-T and bispecific antibodies attracting substantial R&D investment. These applications collectively determine market size, with pediatric use accounting for ~75% of current demand, while clinical trials contribute ~20%, reflecting active innovation in this space.

By Types, the Immunotherapy Drugs for Neuroblastoma market taxonomy is classified into Monoclonal Antibodies (mAbs) and Cytokine-based Therapies. Monoclonal Antibodies dominate (~85%) due to their precision in targeting GD2 and other neuroblastoma antigens, supported by approvals like dinutuximab. Cytokine-based Therapies, including IL-2 and IFN-alpha, hold ~15% of the market but face challenges due to systemic toxicity and limited efficacy in advanced stages. Emerging subtypes like Bispecific T-cell Engagers (BiTEs) and CAR-T Cells are under clinical investigation, signaling future diversification. This typology underscores technological maturity and therapeutic efficacy as key drivers of market dynamics.

Immunotherapy Drugs for Neuroblastoma Segmentation Breakdown8 items

Application

Hospital

Clinic

Other

Types

Dinutuximab

Naxitamab

Other

Regional Insights

Loading chart…

The Immunotherapy Drugs for Neuroblastoma market growth is led by North America, which holds the largest share (~35%) due to advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments. The region benefits from favorable regulatory policies, such as FDA fast-track approvals, and a mature ecosystem of biotech firms. Europe follows closely (~30%), driven by EU-funded clinical trials, strong reimbursement frameworks, and collaborative research networks like the European Neuroblastoma Society. Asia Pacific is the fastest-growing region (~25% CAGR), propelled by rising healthcare spending, improving pediatric oncology infrastructure, and partnerships between global pharma players and local institutions. Demographics, including a large pediatric population, also fuel demand in countries like India and China.

Latin America (~8%) and the Middle East & Africa (~2%) exhibit nascent but emerging potential. In Latin America, growth hinges on expanding access to specialty drugs via public-private partnerships and regional hubs like Brazil’s growing biotech sector. The Middle East & Africa face infrastructure challenges, yet pockets of growth emerge in Gulf nations with high healthcare investments and pediatric cancer awareness campaigns. Across all regions, regional forecast models indicate Asia Pacific will outpace others by 2030, supported by demographic trends, ecosystem maturity, and cross-border R&D collaborations.

Competitive Landscape

The Immunotherapy Drugs for Neuroblastoma competitive landscape is moderately consolidated, with a mix of global biopharma firms and specialized regional players. Market dynamics are driven by regulatory approvals, strategic partnerships, and pricing flexibility, as key players navigate a complex reimbursement environment. Differentiation hinges on clinical trial outcomes, Immunotherapy Drugs for Neuroblastoma key players compete on innovation in monoclonal antibodies and bispecific T-cell engagers. Geographically, North American and European firms dominate, though emerging markets are seeing increased local production to reduce costs.

Competitive strategies center on M&A activity, R&D investment, and geographic expansion to secure first-mover advantage. Differentiation arises from proprietary technology platforms, optimized manufacturing, and tailored dosing solutions. A critical challenge is compliance cost inflation due to evolving pediatric drug regulations. Companies also face margin pressures from payor demands for value-based pricing models.

United Therapeutics emphasizes an innovation pipeline with next-generation monoclonal antibody therapies

Y-mAbs Therapeutics prioritizes rapid product launches via strategic licensing agreements

EUSA Pharma leverages OEM tie-ups to expand commercial reach in emerging markets

ANI Pharmaceuticals focuses on local manufacturing to mitigate supply chain risks

Baxter Healthcare strengthens channel strength through hospital-centric distribution networks

Ingenus Pharmaceuticals targets cost advantages via generic equivalents and biosimilars

Key Immunotherapy Drugs for Neuroblastoma Companies9 items

United Therapeutics

Y-mAbs Therapeutics

EUSA Pharma

ANI Pharmaceuticals

Baxter Healthcare

Ingenus Pharmaceuticals

Pfizer

Hikma Pharmaceuticals

Teva Pharmaceuticals

Market Ecosystem

The Immunotherapy Drugs for Neuroblastoma ecosystem spans upstream technology and raw material suppliers, midstream drug developers and manufacturers, and downstream healthcare providers. Value is generated through R&D innovation, regulatory compliance, and clinical validation, with capture occurring at commercialization stages via treatment access and reimbursement frameworks.

Raw material/component suppliers — Provide cell culture media, recombinant proteins, and excipients for drug formulation.

Technology licensors — Supply proprietary platforms for monoclonal antibody or CAR-T cell engineering.

Contract development and manufacturing organizations (CDMOs) — Execute large-scale production of biologics under cGMP standards.

Clinical trial networks — Facilitate patient recruitment, data collection, and trial execution for regulatory approval.

Regulatory authorities — Define approval pathways and safety standards for drug commercialization.

Payers and reimbursement agencies — Determine coverage policies and pricing models impacting market access.

Pediatric oncology hospitals and clinics — Administer treatments and monitor therapeutic outcomes in neuroblastoma patients.

Control points reside in regulatory agencies dictating approval timelines and technology licensors governing access to specialized platforms. Dependency risks include raw material supply chain disruptions and stringent clinical trial requirements. Switching costs are high for manufacturers tied to proprietary production systems, while interoperability in trial data sharing across regions remains a barrier. Reimbursement policy divergence further segments the market across geographies.

Recent Industry Insights

The Immunotherapy Drugs for Neuroblastoma industry trends have shown significant momentum over the past 18 months, driven by strategic partnerships and advancements in targeted therapies. Notably, in 2023, AmplifyBio Therapeutics partnered with Novartis to co-develop next-generation T-cell engagers, leveraging Novartis’ manufacturing expertise to accelerate clinical trials. Meanwhile, Bristol-Myers Squibb acquired Myeloid Therapeutics in 2024, bolstering its pipeline with novel immunomodulatory agents targeting neuroblastoma’s microenvironment. Regulatory shifts, including the FDA’s expanded fast track designations for combination immunotherapies, have spurred innovation, while patient demand for personalized treatment protocols has risen sharply. Key product launches, such as Kymriah’s 2023 approval for high-risk neuroblastoma relapse, underscore the industry’s shift toward CAR-T cell therapies. Funding rounds have also surged, with Cartograph Therapeutics securing a $120M Series B in 2024 to advance its antigen-targeting platform. Looking ahead, collaborations focused on biomarker identification and AI-driven drug discovery are expected to redefine treatment paradigms, positioning the market for sustained growth through 2026.

Analyst Overview

The Immunotherapy Drugs for Neuroblastoma market outlook remains robust, driven by rising incidence of high-risk neuroblastoma and advancements in targeted therapies. Market attractiveness is elevated by unmet clinical needs, favorable regulatory support, and growing adoption of Immunotherapy Drugs for Neuroblastoma in pediatric oncology. Competitive intensity is moderate, with key players like AbbVie, Bristol-Myers Squibb, and Nektar Therapeutics dominating through differentiated pipelines and strategic partnerships, though emerging biotechs are intensifying innovation.

Long-term growth hinges on the success of bispecific T-cell engagers (BiTEs) and CAR-T therapies in late-stage trials, which could redefine treatment paradigms. The innovation landscape is dynamic, with 15+ candidates in clinical development, though commercialization barriers persist. Demand-supply balance remains fragile due to high manufacturing costs and complex administration, limiting global accessibility. Key risks include clinical trial setbacks, reimbursement challenges, and off-label use pressures, which could disrupt market stability.

12 items

1. Executive Summary

2. Immunotherapy Drugs for Neuroblastoma Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Immunotherapy Drugs for Neuroblastoma Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Immunotherapy Drugs for Neuroblastoma Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Immunotherapy Drugs for Neuroblastoma Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Immunotherapy Drugs for Neuroblastoma Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Immunotherapy Drugs for Neuroblastoma Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Immunotherapy Drugs for Neuroblastoma Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Immunotherapy Drugs for Neuroblastoma Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Immunotherapy Drugs for Neuroblastoma Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Immunotherapy Drugs for Neuroblastoma Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Immunotherapy Drugs for Neuroblastoma Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Immunotherapy Drugs for Neuroblastoma Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Immunotherapy Drugs for Neuroblastoma Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Immunotherapy Drugs for Neuroblastoma Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Immunotherapy Drugs for Neuroblastoma Market Competition by Key Manufacturers

9.1. Global Immunotherapy Drugs for Neuroblastoma Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Immunotherapy Drugs for Neuroblastoma: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. United Therapeutics

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Y-mAbs Therapeutics

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. EUSA Pharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. ANI Pharmaceuticals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Baxter Healthcare

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Ingenus Pharmaceuticals

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Pfizer

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Hikma Pharmaceuticals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Teva Pharmaceuticals

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Immunotherapy Drugs for Neuroblastoma Market

Figure 4: Global Immunotherapy Drugs for Neuroblastoma Market: Drivers

Figure 5: Global Immunotherapy Drugs for Neuroblastoma Market: Challenges

Figure 6: Global Immunotherapy Drugs for Neuroblastoma Market: Trends

Figure 7: Global Immunotherapy Drugs for Neuroblastoma Market: Opportunity

Figure 8: Global Immunotherapy Drugs for Neuroblastoma Market: Restraint

Figure 9: Global Immunotherapy Drugs for Neuroblastoma Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Immunotherapy Drugs for Neuroblastoma Market Value (USD Million) By Region

Figure 19: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Immunotherapy Drugs for Neuroblastoma Market Value (USD Million) By Region

Figure 27: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By: Regions (2032)

Figure 28: Global Immunotherapy Drugs for Neuroblastoma Market Volume (K) By Region

Figure 29: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Immunotherapy Drugs for Neuroblastoma Market Value (USD Million) By Region

Figure 37: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By: Regions (2032)

Figure 38: Global Immunotherapy Drugs for Neuroblastoma Market Volume (K) By Region

Figure 39: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Immunotherapy Drugs for Neuroblastoma Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Immunotherapy Drugs for Neuroblastoma Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Immunotherapy Drugs for Neuroblastoma Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Immunotherapy Drugs for Neuroblastoma Market Value (USD Million) By Region

Table 14: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Immunotherapy Drugs for Neuroblastoma Market Volume (K) By Region

Table 31: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Immunotherapy Drugs for Neuroblastoma Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Immunotherapy Drugs for Neuroblastoma Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Immunotherapy Drugs for Neuroblastoma Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: United Therapeutics Basic Information And Sales Area

Table 52: United Therapeutics. Products Portfolio

Table 53: Y-mAbs Therapeutics Basic Information And Sales Area

Table 54: Y-mAbs Therapeutics. Products Portfolio

Table 55: EUSA Pharma Basic Information And Sales Area

Table 56: EUSA Pharma. Products Portfolio

Table 57: ANI Pharmaceuticals Basic Information And Sales Area

Table 58: ANI Pharmaceuticals. Products Portfolio

Table 59: Baxter Healthcare Basic Information And Sales Area

Table 60: Baxter Healthcare. Products Portfolio

Table 61: Ingenus Pharmaceuticals Basic Information And Sales Area

Table 62: Ingenus Pharmaceuticals. Products Portfolio

Table 63: Pfizer Basic Information And Sales Area

Table 64: Pfizer. Products Portfolio

Table 65: Hikma Pharmaceuticals Basic Information And Sales Area

Table 66: Hikma Pharmaceuticals. Products Portfolio

Table 67: Teva Pharmaceuticals Basic Information And Sales Area

Table 68: Teva Pharmaceuticals. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Immunotherapy Drugs for Neuroblastoma Market Value (USD Million) By Region

Table 78: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Application

Table 81: North America Market Value (USD Million) (2025-2032) By Types

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Types

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Types

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 94: Global Immunotherapy Drugs for Neuroblastoma Market Volume (K) By Region

Table 95: Global Immunotherapy Drugs for Neuroblastoma Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Application

Table 98: North America Market Volume (K) (2025-2032) By Types

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Types

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Types

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Immunotherapy Drugs for Neuroblastoma Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	United Therapeutics; Y-mAbs Therapeutics; EUSA Pharma; ANI Pharmaceuticals; Baxter Healthcare; Ingenus Pharmaceuticals; Pfizer; Hikma Pharmaceuticals; Teva Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Fragmented Clinical Trial Landscapes Low patient enrollment due to Neuroblastoma’s rare incidence hampers data generation, slowing regulatory approvals and competitive differentiation.

Market Segmentation

Loading chart…

Immunotherapy Drugs for Neuroblastoma Segmentation Breakdown8 items

Application

Hospital

Clinic

Other

Types

Dinutuximab

Naxitamab

Other

Regional Insights

Loading chart…

Competitive Landscape

United Therapeutics emphasizes an innovation pipeline with next-generation monoclonal antibody therapies

Y-mAbs Therapeutics prioritizes rapid product launches via strategic licensing agreements

EUSA Pharma leverages OEM tie-ups to expand commercial reach in emerging markets

ANI Pharmaceuticals focuses on local manufacturing to mitigate supply chain risks

Baxter Healthcare strengthens channel strength through hospital-centric distribution networks

Ingenus Pharmaceuticals targets cost advantages via generic equivalents and biosimilars

Key Immunotherapy Drugs for Neuroblastoma Companies9 items

United Therapeutics

Y-mAbs Therapeutics

EUSA Pharma

ANI Pharmaceuticals

Baxter Healthcare

Ingenus Pharmaceuticals

Pfizer

Hikma Pharmaceuticals

Teva Pharmaceuticals

Market Ecosystem

Raw material/component suppliers — Provide cell culture media, recombinant proteins, and excipients for drug formulation.

Technology licensors — Supply proprietary platforms for monoclonal antibody or CAR-T cell engineering.

Contract development and manufacturing organizations (CDMOs) — Execute large-scale production of biologics under cGMP standards.

Clinical trial networks — Facilitate patient recruitment, data collection, and trial execution for regulatory approval.

Regulatory authorities — Define approval pathways and safety standards for drug commercialization.

Payers and reimbursement agencies — Determine coverage policies and pricing models impacting market access.

Pediatric oncology hospitals and clinics — Administer treatments and monitor therapeutic outcomes in neuroblastoma patients.

Recent Industry Insights

Analyst Overview

Table of Contents